1. Home
  2. FULC vs MGNX Comparison

FULC vs MGNX Comparison

Compare FULC & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

N/A

Current Price

$3.69

Market Cap

281.1M

Sector

Health Care

ML Signal

N/A

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

N/A

Current Price

$1.97

Market Cap

262.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FULC
MGNX
Founded
2015
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
281.1M
262.4M
IPO Year
2019
2013

Fundamental Metrics

Financial Performance
Metric
FULC
MGNX
Price
$3.69
$1.97
Analyst Decision
Hold
Buy
Analyst Count
5
7
Target Price
$3.67
★ $8.00
AVG Volume (30 Days)
★ 1.2M
1.0M
Earning Date
11-12-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $149,500,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$2.83
$1.32
52 Week High
$15.74
$5.08

Technical Indicators

Market Signals
Indicator
FULC
MGNX
Relative Strength Index (RSI) 45.53 26.92
Support Level $3.62 $1.93
Resistance Level $3.81 $3.39
Average True Range (ATR) 0.06 0.18
MACD -0.00 0.01
Stochastic Oscillator 7.69 11.86

Price Performance

Historical Comparison
FULC
MGNX

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

About MGNX MacroGenics Inc.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

Share on Social Networks: